Equillium, Inc. (EQ)

US — Healthcare Sector
Peers: LYRA  HOOK  LIAN  JSPR  CINGW  SABS  ANEB  CVKD  MNPR  SPRO  BOLT  CHRS  GRCL  NLTX  IKNA  HOWL  EWTX  QNRX  KTTA  LIFE  TRVI  CUE  ANTX  BCAB 

Automate Your Wheel Strategy on EQ

With Tiblio's Option Bot, you can configure your own wheel strategy including EQ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol EQ
  • Rev/Share 0.8544
  • Book/Share 0.2972
  • PB 1.1455
  • Debt/Equity 0.0279
  • CurrentRatio 2.7018
  • ROIC -1.3545

 

  • MktCap 12162422.0
  • FreeCF/Share -0.5189
  • PFCF -0.6587
  • PE -0.8663
  • Debt/Assets 0.0176
  • DivYield 0
  • ROE -0.7435

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade EQ Leerink Partners Outperform Market Perform $3 $1 March 28, 2025

News

Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
EQ
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive

After losing some value lately, a hammer chart pattern has been formed for Equillium (EQ), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Read More
image for news Equillium (EQ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients
EQ
Published: March 27, 2025 by: Benzinga
Sentiment: Negative

Equillium, Inc. EQ released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host disease (aGVHD).

Read More
image for news Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients
Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
EQ
Published: March 27, 2025 by: Business Wire
Sentiment: Neutral

LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced topline data from the Phase 3 EQUATOR study evaluating itolizumab in first-line treatment of patients with acute graft-versus-host disease (aGVHD). The study results did not demonstrate a meaningful difference in complete response (CR) or overal.

Read More
image for news Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now
EQ
Published: February 21, 2025 by: Zacks Investment Research
Sentiment: Positive

Equillium (EQ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Read More
image for news Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock
EQ
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Equillium (EQ) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Read More
image for news Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock

About Equillium, Inc. (EQ)

  • IPO Date 2018-10-12
  • Website https://equilliumbio.com
  • Industry Biotechnology
  • CEO Bruce D. Steel
  • Employees 35

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.